How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
Pharma & Biotech
Pharma & Biotech
Thailand approves NERLYNX for HER2+ breast cancer: Will it change relapse prevention?
NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.
Pharma & Biotech
Can Hoth Therapeutics’s topical HT-001 redefine EGFR therapy adherence in cancer supportive care?
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
Pharma & Biotech
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
Pharma & Biotech
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Pharma & Biotech
AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.
Pharma & Biotech
Replacing microbiota rejuvenates aging gut tissue: What new mouse data means for regenerative GI therapies
A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.
Pharma & Biotech
What MDLifespan’s plasma exchange expansion reveals about toxin burden and aging medicine
Find out how MDLifespan and Cenegenics are redefining plasma exchange for inflammation and toxin removal. Could this reshape preventive health care?
Pharma & Biotech
FAR Biotech expands to Madison: What this means for AI-based drug development
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.
Pharma & Biotech
Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?
Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.